Sign In
Buy ABBV
$248.00
-0.0800 (-0.0322%)
At Close: Jul 13, 2026
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
05:06pm, Monday, 13'th Jul 2026
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon
3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors
12:15pm, Monday, 13'th Jul 2026
You need to look beyond the tech sector to find great dividend stocks for the long term.
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
08:15pm, Saturday, 11'th Jul 2026
AbbVie has a portfolio of attractive drugs, including branded products that are off-patent but still highly profitable. The company's acquisition of Apogee helps expand its drug pipeline.
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
08:24pm, Friday, 10'th Jul 2026
On July 10, 2026, AbbVie Inc (ABBV) shares fell 0.7% to a current price of $248.08. This price is down from a 52-week high of $261.64 and remains significantly
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
11:30am, Friday, 10'th Jul 2026
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Thursday, 09'th Jul 2026
In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
10:01am, Thursday, 09'th Jul 2026
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
08:15am, Thursday, 09'th Jul 2026
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
12:15pm, Tuesday, 07'th Jul 2026
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Buy these quality, low-stress stocks for the summer, says Jefferies
11:45am, Tuesday, 07'th Jul 2026
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more th
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
10:45am, Tuesday, 07'th Jul 2026
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.
3 Dividend Aristocrats to Buy in July
08:00am, Tuesday, 07'th Jul 2026
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026.
The Dividend ETF Quietly Outperforming the S&P 500
05:30am, Tuesday, 07'th Jul 2026
This dividend ETF's focus beyond yield continues to pay off for investors.
TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in th
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
11:51am, Monday, 06'th Jul 2026
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
